Poziotinib Shows Promise In EGFR Exon 20 Mutant NSCLC
Hanmi and Spectrum's novel oral pan-HER inhibitor poziotinib shows promising interim results in Phase II study in NSCLC patients with EGFR exon 20 insertion mutations, an unmet need.
You may also be interested in...
Spectrum is expanding a clinical trial with its novel, oral pan-HER inhibitor poziotinib into the first-line treatment of NSCLC with EGFR or HER2 exon 20 insertion mutations, which could provide a much-needed new option for these patients. The move also marks further positive development progress for the drug, which the US firm licensed in from Hanmi.
In a busy month, MD Anderson also partners with Ipsen on an unspecified cancer drug and licenses poziotinib IP to Spectrum. Using IP from UCLA, Bloom launches with focus on neuroprotective epilepsy therapies.
Hanmi is set to focus on other assets in its innovative drug pipeline after it ends development of novel lung cancer drug olmutinib amid ZAI Lab’s recent cancellation of a licensing agreement with the South Korean pharma.